Results 111 to 120 of about 355,585 (385)

Improvement of Hemocompatibility in Passive Cardiovascular Implant Devices

Advanced Therapeutics, EarlyView.
With the ever‐increasing reliance on cardiovascular devices and implants, minimizing their impact on blood is vital for their continued success. This review investigates the common methods of tackling this challenge through careful selections of material and surface modifications.
Shiyen L. Perera, Christoph E. Hagemeyer, Julian A. Smith, Josie Carberry, Be'eri Niego   +4 more
wiley   +1 more source

Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed With Venous Thromboembolism: Evidence-Based Clinical Practice Guideline [PDF]

, 2016
The American Physical Therapy Association (APTA), in conjunction with the Cardiovascular & Pulmonary and Acute Care sections of APTA, have developed this clinical practice guideline to assist physical therapists in their decision-making process when ...
Auten, Beth, Frese, Ethel M., Hillegass, Ellen, Puthoff, Michael, Sobush, Dennis, Thigpen, Mary   +5 more
core   +1 more source

Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]

, 2019
© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A, Gue, Ying X, Kanji, Rahim, Srinivasan, Manivannan, Wellsted, David M, Wyatt, Solange   +5 more
core   +2 more sources

Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update

Medicines, 2019
Background: Over the last ten years, a new class of drugs, known as the direct-acting oral anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy.
Stephanie A. Kustos, P. Fasinu
semanticscholar   +1 more source

NARFL Knockout Triggers Ferroptosis‐Driven Vascular Endothelial Dysfunction

Advanced Science, EarlyView.
NARFL is vital for CIA and oxidative stress resistance. NARFL deletion in HPMEC cells, zebrafish, and mice is lethal and rescued by a Ferroptosis inhibitor. NARFL deficiency disrupted its interaction with CIA proteins, decreased aconitase activity, increased IRP1 activity, induced Fe overload, and led to ferroptosis and oxidative stress, resulting in ...
Hui Hu, Jing Luo, Li Yu, Daoxi Qi, Boyu Li, Yating Chen, Chen Wang, Xiaokang Zhang, Wenzheng Guo, Qiyong Lou, Gang Zhai, Yonglin Ruan, Jianfei Huang, Shengchi Shi, Zhan Yin, Fang Zheng   +15 more
wiley   +1 more source

Anaesthesia Management for High-risk Patients: A Case Study of Lower Limb Amputation on Anti-thrombolytic Therapy [PDF]

Journal of Clinical and Diagnostic Research
Anaesthesia is associated with certain risks in patients on anticoagulant therapy, which need to be addressed according to clinical requirements. Regional anaesthesia is linked to venous thromboembolism, with increased chances of haematoma and bleeding ...
Prachi Deshmukh, Vivek Chakole
doaj   +1 more source

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. [PDF]

, 2014
Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in ...
Amarenco, P, Camm, AJ, Haas, S, Hess, S, Kirchhof, P, Turpie, AG, van Eickels, M   +6 more
core   +2 more sources

Heparin and anticoagulation

Frontiers in Bioscience, 2016
Heparin, a sulfated polysaccharide, has been used as a clinical anticoagulant for over 90 years. Newer anticoagulants, introduced for certain specialized applications, have not significantly displaced heparin and newer heparin-based anticoagulants in most medical procedures.
Akihiro, Onishi, Kalib, St Ange, Jonathan S, Dordick, Robert J, Linhardt   +3 more
openaire   +2 more sources

Cancer Immunotherapy via Disruption of Integrin αvβ3 and CD47 Costabilization on Cancer Cell Surface

Advanced Science, EarlyView.
This study identifies a cancer‐specific interaction between CD47 and integrin αvβ3 that facilitates immune evasion. A rationally designed peptide, PSFL‐NK13, disrupts this axis, enhancing macrophage‐mediated phagocytosis and suppressing tumor growth without inducing anemia.
Peng‐Cheng Yu, Chen‐Xi Yue, Wen‐Zhong Dong, Cui‐Yun Hao, Yi‐Fan Qiao, Di Liu, Xin Zhang, Qi Zhan, Jia‐Bao Yao, Dong‐Ping Wang, Peng Cao, Ying‐Zhe Fan, Ye Yu   +12 more
wiley   +1 more source

EXTENDED ANTICOAGULANT THERAPYIN PATIENTS, WHO SURVIVED PULMONARY EMBOLISM

Атеротромбоз, 2018
The review article discusses the options to extend anticoagulant therapy after completing the main anticoagulant therapy course in patients, who survived pulmonary embolism.
Natalia M. Vorobieva, Elizaveta P. Panchenko   +1 more
doaj   +1 more source